Table 2.
Inhibition of RT-SHIV replication by antiretroviral compounds
| Drugs Category | Anti-HIV drugs | EC50 (μM) |
CC50 (μM) |
Selectivity index(SI) |
|---|---|---|---|---|
| NNRTIs | Efavirenz | 0.002 ± 0.001 | 35.72 ± 25.45 | 17860 |
| Nevirapine | 0.06 ± 0.01 | > 100 | > 1667 | |
| UC781 | 0.003 ± 0.002 | 59.22 ± 6.56 | 19740 | |
| NRTIs | ZIdovudine (AZT) | 0.01 ± 0.01 | > 100 | > 10000 |
| Lamivudine (3TC) | 0.43 ± 0.13 | > 100 | > 233 | |
| Stavudine (D4T) | 0.01 ± 0.01 | 66.48 ± 34.84 | 6648 | |
| Emtricitabine (FTC) | 0.1 ± 0.1 | > 100 | > 1000 | |
| Tenofovir | 0.82 ± 0.62 | > 100 | > 122 | |
| PIs | Ritonavir | 0.1 ± 0.1 | 63.92 ± 43.03 | 639 |
| Indinavir | 0.008 ± 0.008 | > 100 | > 12500 | |
| Saquinavir | 0.004 ± 0.007 | 62.18 ± 32.75 | 15545 |
NNRTIs: Non-nucleoside reverse transcriptase inhibitors; NRTIs: nucleoside RT inhibitors;
PIs: protease inhibitors
EC50: Effective concentration of antiretroviral drug inhibited 50% virus replication.
CC50: Cytotoxic concentration of antiretroviral drug showed cytotoxic effect in 50% of cells.
SI: selectivity index represents a ratio of CC50 to EC50.